2004-2013年美国膀胱尿路上皮癌根治性膀胱切除术后辅助放疗的国家实践模式与总生存
基于美国国家癌症数据库2004-2013年根治性膀胱切除术后具有不良病理特征的膀胱尿路上皮癌病例,分析辅助放疗的使用模式及对总生存的影响。辅助放疗使用率从2004年3.1%降至2013年1.7%(p=0.03),全队列中与总生存无独立关联(p=0.54),亚组分析提示手术切缘阳性患者可能获益(HR 0.73;p=0.047)。
要点
- 辅助放疗使用率从2004年3.1%下降至2013年1.7%(p=0.03)
- 全队列中辅助放疗与总生存无独立关联(p=0.54)
- 手术切缘阳性患者中辅助放疗提示总生存获益(HR 0.73;p=0.047)
核心结论
- 在美国,根治性膀胱切除术后具有不良病理特征的患者中辅助放疗不常用且使用率随时间下降。
- 辅助放疗可能对手术切缘阳性的根治性膀胱切除术后患者有总生存获益。
研究设计与样本
- 回顾性分析美国国家癌症数据库2004至2013年根治性膀胱切除术后具有不良病理特征的膀胱尿路上皮癌病例,分为辅助放疗组与无辅助放疗组。
- 采用多变量Cox回归和对数秩检验分析肿瘤学结局。
主要发现
- 辅助放疗使用率从2004年3.1%下降至2013年1.7%(p=0.03)。
- pT3期、pT4期和手术切缘阳性(任何pT分期)患者中辅助放疗使用率分别为1.4%、4.0%和5.2%。
- 辅助放疗的预测因素包括手术切缘阳性(OR 3.4;p<0.0001)、pT4期(OR 2.6;p=0.02)、社区中心(OR 2.1;p<0.0001)和女性(OR 1.8;p<0.0001)。
- 总生存较差的危险因素包括年龄、更高肿瘤分期和合并症、手术切缘阳性、淋巴结阳性以及淋巴结清扫不充分(清扫<10枚淋巴结;均p<0.001)。
- 全队列中辅助放疗与总生存无独立关联(p=0.54),但亚组分析提示手术切缘阳性患者有总生存获益(HR 0.73;p=0.047)。
局限性
- 局限性包括回顾性设计和对癌症特异性生存的细节有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant radiation therapy (ART) after radical cystectomy (RC) for urothelial bladder cancer (UBC) may play a role in the management of muscle-invasive BC, particularly in patients with locally advanced disease and adverse pathologic features (pT3/4 or positive surgical margins [PSMs]). Evidence regarding the effect of ART on overall survival (OS) is lacking. OBJECTIVE: To evaluate national practice patterns for the use of ART and assess its impact on OS for patients with adverse pathologic features (APF) after RC. DESIGN, SETTING, AND PARTICIPANTS: Using the National Cancer Data Base, we analyzed all UBC cases with APF after RC from 2004 to 2013. Patients were divided into ART and no-ART groups. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Relationships with oncological outcomes were analyzed using multivariable Cox regression and log-rank analyses. RESULTS AND LIMITATIONS: Use of ART decreased during the study period from 3.1% in 2004 to 1.7% in 2013 (p=0.03). ART was administered in 1.4%, 4.0% and 5.2% of patients with pT3 UBC, pT4 UBC, and PSMs (any pT stage), respectively. The rate of ART was significantly higher among younger ages, female sex, low-volume hospitals, nonacademic community care centers, higher stages, PSMs, perioperative chemotherapy, and lymph node-positive disease. Predictors of ART receipt were PSMs (odds ratio [OR] 3.4; p<0.0001), pT4 (OR 2.6; p=0.02), community based centers (OR 2.1; p<0.0001), and female sex (OR 1.8; p<0.0001). Risk factors for worse OS included age, higher tumor stage and comorbidities, PSMs, positive nodes, and suboptimal lymph node dissection (<10 nodes removed; all p<0.001). ART was not independently associated with better OS in the full cohort (p=0.54). However, subgroup analyses suggested an OS benefit for patients with PSMs (hazard ratio 0.73; p=0.047). Limitations include the retrospective design and limited details regarding cancer-specific survival. CONCLUSIONS: Use of ART for APF following RC is not common in the USA and the rate of ART has been decreasing over time. ART may have an OS benefit after RC for patients with PSMs. PATIENT SUMMARY: In this report we looked at the outcomes for patients with locally advanced bladder cancer receiving adjuvant radiation therapy following cystectomy in a large US population. We found that adding radiation therapy after removing the bladder cancer may have some survival benefits for patients with positive surgical margins.
引用
- Bateni ZH, Pearce SM, Zainfeld D, et al. National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013. Eur Urol Oncol. 2018. PMID: 31317867. doi:10.1016/j.euo.2018.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。